Evidence map›Paper›PMID 41957950›Full record

ArticleOncoimmunology2026

Mirte van der Heijden, James Hugo Armstrong Clubb, Pande Putu Erawijantari, Aki Ronkainen, Victor Arias, Elise Jirovec, Tatiana Kudling, Santeri Artturi Pakola, Nea Ojala, Lyna Haybout and 10 more

2 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04695327 phase1completednot on this map

A Phase 1, Open-Label, Dose-escalation Clinical Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123) in Patients With Injectable Solid Tumors

TypeinterventionalSponsorTILT Biotherapeutics Ltd.Ran2021 to 2025Enrolled32ConditionsSolid TumorArmsTILT-123
NCT05271318 phase1 / phase2active not recruitingnot on this map

A Two-part, Phase I/Ib, Open-Label, Dose-escalation Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123) in Combination With Pembrolizumab (Phase I Part) and Pembrolizumab and Pegylated Liposomal Doxorubicin (Phase Ib Part) in Patients With Platinum Resistant or Refractory Ovarian Cancer

TypeinterventionalSponsorTILT Biotherapeutics Ltd.Ran2022 to 2027Enrolled29ConditionsPlatinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal CarcinomaArmsTILT-123, pembrolizumab, pegylated liposomal doxorubicin
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Mirte van der HeijdenCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.ORCID 0009-0000-4123-6464
James Hugo Armstrong ClubbCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-9146-4817
Pande Putu ErawijantariDepartment of Computing, Faculty of Technology, University of Turku, Turku, Finland.
Aki RonkainenGreen Chemistry, Metropolia University of Applied Sciences, Helsinki, Finland.
Victor AriasCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-3631-2896
Elise JirovecCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.ORCID 0009-0004-0606-6577
Tatiana KudlingCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.ORCID 0000-0003-4481-1617
Santeri Artturi PakolaCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.ORCID 0000-0001-6235-8612
Nea OjalaCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
Lyna HayboutCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.ORCID 0009-0005-5170-5611
Saru BasnetCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.ORCID 0000-0003-0268-5982
Susanna Grönberg-Vähä-KoskelaCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
Sini Karoliina RaatikainenTILT Biotherapeutics, TILT Biotherapeutics Ltd, Helsinki, Finland.
Otto HemminkiCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
Anna KanervaCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
Dafne Carolina Alves QuixabeiraCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.ORCID 0000-0003-2614-3942
Victor Cervera-CarrasconCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.ORCID 0000-0001-6684-3666
João Manuel Dos SantosCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
Leo LahtiDepartment of Computing, Faculty of Technology, University of Turku, Turku, Finland.
Akseli HemminkiCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accumulating evidence implicates the microbiome as an important determinant of clinical outcomes in cancer therapies; however, the role of the microbiome in oncolytic virus therapy remains largely unexplored. We investigated the gut microbiome of cancer patients following treatment with the oncolytic adenovirus igrelimogene litadenorepvec (Ad5/3-E2F-d24-hTNF-IRES-hIL2; TILT-123). Baseline fecal samples from phase I clinical trials (NCT04695327 and NCT05271318) were analyzed using shotgun metagenomic sequencing and compared to treatment outcomes. A higher relative abundance of

Indexed as

ActinobacteriaAdenoviridaeFatty Acids, VolatileGastrointestinal MicrobiomeNeoplasmsOncolytic VirotherapyOncolytic VirusesAnimalsClinical Trials, Phase I as TopicFecesFemaleHumansMaleMiceFatty Acids, VolatileAdenoviruscancer therapyfecal microbiomegut microbiomeoncolytic virus therapy

Identifiers

PMID41957950
PMCPMC13374768

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.